Centre does not expect the timelines of the covid-19 immunization programme to be impacted despite a subject expert committee (SEC) deferring its decision on recommending emergency licensure for the vaccines developed by Bharat Biotech International and Serum Institute of India.“We have to be more than reasonably satisfied about safety, immunogenicity, and effectiveness (when we give an emergency use authorization).